Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients-Reference-Cited by-同舟云学术

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients

Published:2016-07-25 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Aktas Bahriye, ,Kasimir-Bauer Sabine,Müller Volkmar,Janni Wolfgang,Fehm Tanja,Wallwiener Diethelm,Pantel Klaus,Tewes Mitra

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2587-4

Reference47 articles.

1. Amir E, Miller N, Geddie W, et al. Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer. JCO. 2012;30(6):587–92.

2. Curigliano G, Bagnardi V, Viale G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol. 2011;22(10):2227–33.

3. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009:mdp028.

4. Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas. J Pathol. 2004;203(4):918–26.

5. Amir E, Clemons M, Purdie CA, et al. Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012;38(6):708–14.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic significance of circulating tumor cell enumeration and HER2 expression by a novel automated microfluidic system in metastatic breast cancer;BMC Cancer;2024-08-29

2. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells—The DETECT III Clinical Trial;Clinical Chemistry;2024-01

3. Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications;The Journal of Liquid Biopsy;2023-12

4. CTCs in Early Breast Cancer;Circulating Tumor Cells;2023

5. A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer;Frontiers in Oncology;2022-12-21